Spots Global Cancer Trial Database for Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Official Title: A Multi-center, Phase II Study to Evaluate Efficacy and Safety of Perioperative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel (FLOT) and Trastuzumab in Combination With Toripalimab in Patients With HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Study ID: NCT05715931
Study Description
Brief Summary: This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Huzhou Central Hospital, Huzhou, Zhejiang, China
Lishui Central Hospital, Lishui, Zhejiang, China
Ningbo First Hospital, Ningbo, Zhejiang, China
Ningbo Medical Center LiHuiLi Hospital, Ningbo, Zhejiang, China
Ningbo Second Hospital, Ningbo, Zhejiang, China
Taizhou Hospital, Taizhou, Zhejiang, China
Contact Details
Name: Jiren Yu
Affiliation: First Affiliated Hospital of Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
